ANGLE plc, a global leader in liquid biopsy technology, has recently achieved a major breakthrough in cancer diagnostics, unveiling results from DNA molecular analysis of patient blood samples. These results provide an unprecedented insight into the individual progression of cancer and open new avenues for treatment.

Revolutionizing Cancer Diagnostics with Parsortix System

ANGLE’s expansion of the Parsortix system into DNA molecular analysis using third-party Next Generation Sequencing (NGS) systems marks a pivotal moment in cancer research and diagnosis. The company has developed innovative sample-to-answer solutions for real-time NGS DNA analysis of both ctDNA (cell-free DNA fragments) and CTCs (circulating tumor cells) from a single blood sample.

The recent results from forty-seven patient samples across breast, lung, prostate, and ovarian cancers analyzed for both ctDNA and CTC-DNA using an Illumina NGS system are groundbreaking. They revealed that widely accepted actionable DNA variants, crucial for cancer treatment, were identified in CTCs but not in ctDNA in a significant percentage of cases. This discovery has the potential to revolutionize the way cancer is treated.

The Potential of Combined CTC-DNA and ctDNA Profiling

ANGLE’s approach to molecular profiling of CTC-DNA alongside ctDNA from the same blood sample could dramatically change cancer treatment. Regular blood tests could enable oncologists to track the clonal evolution of a patient’s cancer, informing treatment decisions, monitoring response, highlighting drug resistance mechanisms, and signaling disease progression. This approach aims to improve patient outcomes and focus healthcare expenditure by supporting the best therapy choices.

Clinical Implications and Future Prospects

ANGLE will leverage these clinical results to expand its product sales and pharma services offerings, providing sample-to-answer DNA molecular solutions. The company plans to work with key opinion leaders and clinicians to expedite the clinical adoption of this combined molecular profiling approach.

Dr. Karen Miller, ANGLE’s Chief Scientific Officer, emphasized the significance of these findings, noting the high levels of additional variants in CTCs that are not present in ctDNA. This could provide crucial information for clinicians to base their treatment options.

Andrew Newland, ANGLE’s Chief Executive Officer, expressed pride in this achievement, highlighting it as a major step in delivering transformational benefits to cancer patients through a simple blood test.

Technical Background and Future Directions

Utilizing its Parsortix system, ANGLE has pioneered the combined analysis of ctDNA and CTCs from the same blood sample. This process offers real-time analysis of cancer progression in both living and dead cancer cells, providing additional clinically relevant information. The results demonstrate the presence of DNA variants in every patient sample, with some variants being targeted by FDA-approved drugs.

In addition to DNA analysis, the CTC sample offers potential for extending analysis to RNA, protein, and morphological analysis, making it an invaluable tool for personalized cancer care.

As ANGLE continues to engage with industry leaders like Illumina, the implications of this breakthrough for cancer clonal evolution and patient treatment are immense, setting a new standard in cancer diagnostics and treatment.

  Andrew Newland, ANGLE plc, Cancer Diagnosis, DNA Molecular Analysis, Dr. Karen Miller, Liquid Biopsy, Next Generation Sequencing, Oncology